TransMedics Group, Inc.

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

TMDX$93.79+6.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TransMedics Group, Inc.
Date: February 24, 2026	By:	/s/ Gerardo Hernandez
		Gerardo Hernandez
		Chief Financial Officer and Treasurer

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

Waleed H. Hassanein
Name	Title	Date
/s/ Waleed H. Hassanein, M.D.	President, Chief Executive Officer, Director	February 24, 2026
/s/ Gerardo Hernandez	Chief Financial Officer and Treasurer	February 24, 2026
Gerardo Hernandez
/s/ James R. Tobin	Chairman of the Board of Directors	February 24, 2026
James R. Tobin
/s/ Edward M. Basile	Director	February 24, 2026
Edward M. Basile
/s/ Thomas J. Gunderson	Director	February 24, 2026
Thomas J. Gunderson
/s/ Edwin M. Kania, Jr.	Director	February 24, 2026
Edwin M. Kania, Jr.
/s/ David Weill, M.D.	Director	February 24, 2026
David Weill, M.D.
/s/ Merilee Raines	Director	February 24, 2026
Merilee Raines
/s/ Stephanie Lovell	Director	February 24, 2026
Stephanie Lovell

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.